



Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078728-0106	SERIAL NO. 09/833,745
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Joseph ROBERTS et al.	
				FILING DATE 04/13/2001	GROUP ART UNIT Unassigned 1652
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
<i>CP</i>	A14	Hakii et al., "Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanoylphorbol-13-acetate (TPA)			
		Type tumor promoter in two-stage mouse skin carcinogenesis", Cancer Research Clinical Oncology, 1986, III , pp. 111-114 .			
<i>CP</i>	A15	Mitra et al., "Histamine and Cis-Urocanic Acid Augment Tumor Necrosis Factor-Alpha Mediated Induction of Keratinocyte Intercellular Adhesion Molecule-1 Expression", Journal of Cellular Physiology 156:348-357, 1993			
		Wiley-Liss, Inc.			
<i>CP</i>	A16	Stolfi et al., "Chemotherapeutic Activity of L-Histidinol against Spontaneous, Autochthonous Murine Breast Tumors", Chemotherapy 1990, 36:435-440.			
		Warrington et al., "L-Histidinol Reverses Resistance to Cisplatin and Other Antineoplastic Agents in a Tumorigenic Epithelial Cell Line", Anticancer Research 16:3641-3646, 1996.			
<i>CP</i>	A17	Warrington et al., "Reversal of the Multidrug-Resistant Phenotype of Chinese Hamster Ovary Cells by L-Histidinol", Journal of the National Cancer Institute 79:803-807, 1987.			
		Warrington et al., "Improved Treatment of Disseminated B16f10 Melanoma in Mice with Anticancer Drugs in Combination with L-Histidinol", Anticancer Research 11:1869-1874, 1991.			
<i>CP</i>	A19	Warrington et al., "Susceptibility of Human Colon Carcinoma Cells to Anticancer Drugs Is Enhanced by L-Histidinol", Anticancer Research 14:367-372, 1994.			
		Warrington et al., "L-Histidinol Increases the Vulnerability of Cultured Human Leukemia and Lymphoma Cells to Anticancer Drugs", Anticancer Research 13:2107-2112, 1993.			
<i>CP</i>	A21	Warrington et al., "L-Histidinol in experimental cancer chemotherapy: improving the selectivity and efficacy of Anticancer drugs, eliminating metastatic disease and reversing the multidrug-resistant phenotype", Biochem, Cell Biol., Vol. 70, 365-375, 1992.			
		Zaharko et al., "L-Histidinol: Preclinical Therapeutic Studies in Combination with Antitumor Agents and Pharmacokinetic Studies in Mice", Cancer Research 52, 3604-3609, July 1992.			
<i>CP</i>	A23	Warrington et al., "L-Histidinol Selectively Modulates Daunomycin Toxicity in Normal and Tumorigenic Kidney Epithelial Cells", Anticancer Research 16:3629-3634, 1996.			
		Badary et al., "Effect of L-Histidinol on Cisplatin Nephrotoxicity in the Rat", Karger AG, Basel 0028-2766/97/0774-0435.			
<i>CP</i>	A25	Al-Shabanah et al., "Effects of L-Histidinol On The Antitumor Activity and Acute Cardiotoxicity of Doxorubicin In Mice", Pharmacological Research, Vol. 38, No. 3, 1998, Article Number 1980355.			
		Al-Shabanah et al., "Effects of L-Histidinol On The Antitumor Activity and Acute Cardiotoxicity of Doxorubicin In Mice", Pharmacological Research, Vol. 38, No. 3, 1998, Article Number 1980355.			
EXAMINER <i>CP</i>		DATE CONSIDERED 10/31/02			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.					

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)		078728-0106	09/833,745
		APPLICANT Joseph ROBERTS et al.	
		FILING DATE 04/13/2001	GROUP ART UNIT <u>1652</u> Unassigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
C/P	A27	Badary, "L-Histidinol Attenuates Fanconi Syndrome Induced by Ifosfamide in Rats", Karger Ag, Basel, 1018-7782/99/0074-323-327. <u>11990 Exp. Nephrol, 725-327.</u>	
C/P	A28	Zaharko et al., "L-Histidinol: Preclinical Therapeutic Studies in Combination with Antitumor Agents and Pharmacokinetic Studies in Mice", Cancer Research 52, 3604-3609, July 1, 1992.	
C/P	A29	U.S. Department of Health and Human Services, "Hypothermia-Related Deaths, Virginia, November 1996-April 1997, December 12, 1997, Vol. 46, No. 49, pp. 1162-1165.	
C/P	A30	Noonan et al., "Immunosuppression by ultraviolet B radiation: initiation by urocanic acid", Immunology Today, Vol. 13, No. 7, 1992, pp. 250-254.	
C/P	A31	Altschul et al., "Gapped BLAST and PSA-BLAST: a new generation of protein database search programs", Nucleic Acids Research, Vol. 25, No. 17, 1997, pp. 3389-3402.	
C/P	A32	Gish et al., "Identification of protein coding regions by database similarity search", Nature Genetics, Vol. 3, 1993, pp. 266-272.	
C/P	A33	Madden et al., "[9] Applications of Network BLAST Server", Methods in Enzymology, Vol. 266, pp.131-141.	
C/P	A34	Altschul et al., "Basic Local Alignment Search Tool", J. Mol. Biol. Vol. 215, 1990, pp. 403-410.	
C/P	A35	Zhang et al., "PowerBLAST: A New Network BLAST Application for Interactive or Automated Sequence Analysis and Annotation", Genome Research, Vol. 7, 1997, pp. 649-656.	
C/P	A36	Newman et al., "Selective Killing of Transformed Cells by Methotrexate with Histidine Deprivation or with Amino Alcohols", Cancer Research Vol 43, October 1983, pp. 4703-4708.	
C/P	A37	Pardee et al., "Animal Cell Cycle", Ann. Rev. Biochem, Vol. 47, 1978, pp. 715-50.	
C/P	A38	Pardee, "A Restriction Point for Control of Normal Animal Cell Proliferation", Proc. Nat. Acad. Sci., Vol 71, No. 4, 1974, pp. 1286-1290.	
C/P	A39	Warrington, "A Novel Approach for Improving the Efficacy of Experimental Cancer Chemotherapy Using Combinations of Anticancer Drugs and L-Histidinol", Anticancer Research, Vol. 6, 1986, 451-464.	
C/P	A40	Warrington, "L-Histidinol in experimental cancer chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and reversing the multidrug-resistant phenotype", Biochem. Cell Biol. Vol. 1992, pp. 365-375.	
C/P	A41	Hanson et al., "Epidermal trans-urocanic acid and the UV-A-induced photoaging of the skin", Proc. Natl. Acad. Sci., Vol. 95, 1998, pp. 10576-10578.	
C/P	A42	Norval, et al., "The Role of Urocanic Acid In UV-Induced Immunosuppression: Recent Advances (1992-1994), Photochemistry and Photobiology, Vol. 62, No. 2, 1995, pp. 209-217.	
EXAMINER 		DATE CONSIDERED <u>10/31/02</u>	
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.			

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078728-0106		SERIAL NO. 09/833,745	
INFORMATION DISCLOSURE CITATION AUG 09 2001 (Use several sheets if necessary)				APPLICANT Joseph ROBERTS et al.			
				FILING DATE 04/13/2001		GROUP ART UNIT Unassigned	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)							
CIP	A43	Kripke, "Ultraviolet Radiation and Immunology: Something New Under the Sun-Presidential Address", Cancer Research, Vol. 54, 1994, pp. 6102-6105.					
CIP	A44	Logan et al., "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci., Vol. 81, June 1994, pp. 3655-3659.					
CIP	A45	Rosenberg et al., "Grafting Genetically Modified Cells to the Damaged Brain: Restorative Effects of NGF Expression", Science, Vol. 242, December 16, 1988, pp. 1575-2578.					
CIP	A46	Wolff et al., "Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease", Proc. Natl. Acad. Sci., Vol. 86, November 1989, pp. 9011-9014.					
CIP	A47	Hodgson, "The Vector Void in Gene Therapy", Bio/Technology Vol. 13, March 1995, pp. 222-225.					
CIP	A48	Caplen et al., "Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis", Nature Medicine, Vol. 1, Number 1, 1995, pp. 39-46.					
CIP	A49	Zhu et al., "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice", Science, Vol. 261, July 9, 1993, pp. 209-211.					
CIP	A50	Berkner, "Development of Adenovirus Vectors for the Expression of Heterologous Genes", BioTechniques, Vol. 6, No. 7, 1988, pp. 616-626.					
CIP	A51	Trapnell, "Adenoviral vectors for gene transfer", Advanced Drug Delivery Reviews, Vol. 12, 1993, pp. 185-199.					
CIP	A52	Monks, "Feasibility of a High-Flux Anticancer drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines", Journal of the National Cancer Institute, Vol. 83, No. 11, June 5, 1991, pp. 757-766.					
EXAMINER CIP				DATE CONSIDERED 10/31/02			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/833,745
		Filing Dat	04/13/2001
Date Submitted: May 10, 2002 (use as many sheets as necessary)		First Named Inventor	Joseph ROBERTS
		Group Art Unit	4645 <i>LEB</i>
Sheet 1 of 1		Examiner Name	Unassigned <i>72661501</i>
		Attorney Docket Number	078728-0106

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
<i>CA</i>	B1	DE FABO et al. "Altered skin cytokine environment after UVB irradiation in UCA-deficient Histidinemic C57BL/6-Ha ^{Edi} mice," <u>Photochemisrty and Photobiology</u> , Vol. 69, 06/1999, pp. 18S-19S, 27 th Annual Meeting of the American Society of Photobiology, Washington, DC.	<div style="writing-mode: vertical-rl; transform: rotate(180deg);"> RECEIVED MAY 13 2002 TECH CENTER 1600/2900 </div>
	B2	BRAND et al. "Histidine ammonia-lyase from rat liver. Purification properties, and inhibition by Substrate analogues," <u>Biochemistry</u> , Vol. 15, No. 9, 1976, pp. 1814-1821.	

Examiner Signature	<i>MAH</i>	Date Considered	10/4/02
--------------------	------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.